To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Dronabinol effective in reducing central lesion pain from multiple sclerosis after 3-week treatment

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
September 2018

Dronabinol effective in reducing central lesion pain from multiple sclerosis after 3-week treatment

Vol: 7| Issue: 9| Number:12| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

BMJ. 2004 Jul 31;329(7460):253

Contributing Authors:
FW Bach TS Jensen KB Svendsen

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

24 patients experiencing central lesion pain due to multiple sclerosis were randomly assigned to receive either dronabinol (maximum of 5mg twice per day) or placebo for 3 weeks. They then underwent a washout period of at least 3 weeks, and were crossed-over to receive the other intervention for 3 weeks. Patients were assessed on the median spontaneous pain intensity, radiating pain intensity, pain...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue